Testing a new injection for swelling after retinal vein blockage
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new medicine called SMO1 for people with vision loss and swelling in the eye caused by a blocked vein in the retina. It involves regular eye injections to see if the medicine can reduce swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You have a blocked vein in the retina either within the last 12 months (branch) or 9 months (central).
- The swelling in your affected eye must be at least 300 micrometers thick on an OCT scan.
- Your best corrected vision in the affected eye must be between 20/200 and 20/50 on an eye chart.
- You must not have other major eye problems like uncontrolled glaucoma, severe cataracts, or bleeding in the eye that would prevent vision improvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
This trial tests whether switching from anti-VEGF injections to a special laser is better than continuing injections alone for people with diabetic macular edema whose central retinal thickness has dropped below 400 microns after the first year of treatment.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Hear when a new Retinal Vein Occlusion With Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.